Mindpeak and Discovery Life Sciences partnered to apply AI-assisted pathology workflows to tissue biomarker analysis, aiming to streamline clinical trials and reduce variability in slide interpretation. Under the agreement, Mindpeak’s AI platform and microdissection algorithms will be paired with Discovery’s biomarker services spanning flow cytometry and histopathology. The companies said the approach is intended to improve biomarker quantification and reproducibility between pathologists—an issue that can complicate endpoint assessments in translational programs. The partnership also includes AI-enabled pathology workflow support and pathologist training components, with Discovery noting prior collaboration work including an AI tissue analysis panel with PathAI. The announcement signals further demand for automation and standardized biomarker reads as sponsors try to de-risk clinical trial variability and speed translational data turnaround.